There is much evidence in the literature indicating that antibodies against endothelin type A receptor (anti-ETAR) may play a role in the pathogenesis of PAH and dilated cardiomyopathy [13,14,15,16]. Here, EDNRA is linked to dilated cardiomyopathy.